Bioceltix Balance Sheet

Financials in millions PLN. Fiscal year is January - December.

Millions PLN. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar '26 Mar 31, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Cash & Equivalents	60.79	68.4	33.63	9.31	4.12	6.05
Cash & Short-Term Investments	60.79	68.4	33.63	9.31	4.12	6.05
Cash Growth	86.64%	103.38%	261.25%	125.97%	-31.96%	88.98%
Accounts Receivable	3.91	2.73	4.97	1.88	0.23	0.44
Inventory	0.2	0	0.01	0.01	0	0
Other Current Assets	0.18	0.16	0.81	0.02	0.01	0.01
Total Current Assets	65.08	71.29	39.42	11.21	4.36	6.51
Net Property, Plant & Equipment	5.11	3.92	2.4	1.48	1.46	1.53
Other Long-Term Assets	0.42	0.42	0.03	0.04	0.17	0.16
Total Assets	70.61	75.63	41.85	12.74	7.65	8.2
Accounts Payable	2.42	1.81	2.91	1.89	1.56	0.89
Accrued Expenses	-	-	-	-	-	0.22
Other Current Liabilities	-	0	0.01	0.03	0.56	0.93
Total Current Liabilities	2.42	1.81	2.91	1.89	1.56	0.89
Long-Term Debt	0.06	0.09	0.15	0.08	0.18	0.15
Other Long-Term Liabilities	0.54	0.46	0.38	0.3	0.79	1.21
Total Long-Term Liabilities	0.6	0.55	0.53	0.38	0.97	1.36
Total Liabilities	3.02	2.36	3.44	2.27	2.5	2.2
Common Stock	0.55	0.55	0.49	0.41	0.34	0.33
Additional Paid-in Capital	87.51	87.52	52.82	23.8	14.44	15.14
Accumulated Other Comprehensive Income	-	0	0	0	4.36	0
Retained Earnings	-20.48	-14.8	-14.9	-13.69	-13.99	-9.47
Shareholders' Equity	67.59	73.28	38.42	10.47	5.15	6
Total Liabilities & Equity	70.61	75.63	41.85	12.74	7.65	8.2
Total Debt	0.06	0.09	0.15	0.08	0.18	0.15
Net Cash (Debt)	60.73	68.31	33.48	9.23	3.94	5.91
Net Cash Growth	87.42%	104.02%	262.61%	134.25%	-33.24%	86.47%
Net Cash Per Share	11.79	13.67	7.38	2.23	1.01	1.87
Book Value	67.59	73.28	38.42	10.47	5.15	6
Book Value Per Share	13.12	14.66	8.47	2.53	1.31	1.90
Tangible Book Value	67.59	73.28	38.42	10.47	5.15	6
Tangible Book Value Per Share	13.12	14.66	8.47	2.53	1.31	1.90